Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 6/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150259 | 0.89 | MEN1 (0.55) | LMNAPRKCIPRKCZTSHRMEN1 | |
| SCHEMBL10150266 | 0.88 | LMNA (0.56) | LMNAPRKCIPRKCZTSHRMEN1 | |
| SCHEMBL10150269 | 0.84 | PRKCI (0.48) | LMNAPRKCIPRKCZTSHRMEN1 | |
| SCHEMBL10150275 | 0.82 | MEN1 (0.58) | LMNAHTTPRKCIPRKCZTSHR | |
| SCHEMBL5735962 | 0.80 | KDM4E (0.48) | LMNAHTTMTORTLR9KDM4E | |
| SCHEMBL5735841 | 0.80 | PIK3CA (0.56) | LMNAMTORTLR9KDM4EALDH1A1 | |
| SCHEMBL10150246 | 0.79 | METAP1 (0.61) | LMNAMTORTSHRKMT2AMAPT | |
| SCHEMBL5733333 | 0.77 | KDM4E (0.56) | LMNAHTTMTORKDM4EALDH1A1 | |
| SCHEMBL8297541 | 0.76 | PIK3CA (0.57) | MTORKDM4EALDH1A1TSHRMEN1 | |
| SCHEMBL8299279 | 0.75 | PIK3CA (0.56) | LMNAMTORKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | KCNQ1, KCNN2, KCNH3 | LMNA 1783/4885HTT 449/4885MTOR 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.